APOA1 and atherosclerosis: Therapeutic approaches targeting ApoA-I, including infusion therapies and mimetic peptides, have shown mixed results in clinical trials, highlighting ongoing challenges.<h4>Conclusion</h4>ApoA-I remains a promising biomarker and therapeutic target in ASCVD, though its clinical application is complicated by biological and methodological variability.